Volume 66, Issue 3, Pages (September 2014)

Slides:



Advertisements
Similar presentations
Volume 69, Issue 5, Pages (May 2016)
Advertisements

Volume 68, Issue 6, Pages (December 2015)
European Urology Focus
The PSA Era is not Over for Prostate Cancer
Volume 60, Issue 2, Pages (August 2011)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Testosterone Therapy in Men With Prostate Cancer
David Lorente, Karim Fizazi, Christopher Sweeney, Johann S. de Bono 
European Urology Focus
Volume 70, Issue 6, Pages (December 2016)
Volume 56, Issue 6, Pages (December 2009)
Volume 68, Issue 6, Pages e129-e131 (December 2015)
Volume 67, Issue 4, Pages (April 2015)
Volume 74, Issue 2, Pages (August 2018)
Volume 68, Issue 2, Pages (August 2015)
Volume 52, Issue 3, Pages (September 2007)
Prostate Cancer Epidemic in Sight?
Failure to Achieve Castration Levels in Patients Using Leuprolide Acetate in Locally Advanced Prostate Cancer  Olav Erich Yri, Trine Bjoro, Sophie D.
Volume 63, Issue 2, Pages (February 2013)
Volume 65, Issue 5, Pages (May 2014)
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
Volume 52, Issue 3, Pages (September 2007)
Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer  Semini Sumanasuriya, Aurelius Omlin, Andrew Armstrong, Gerhardt Attard, Kim.
Volume 65, Issue 1, Pages (January 2014)
Volume 71, Issue 1, Pages 1-3 (January 2017)
Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka 
Volume 70, Issue 4, Pages (October 2016)
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Volume 70, Issue 3, Pages (September 2016)
Prostate Cancer Detection: A View of the Future
Volume 70, Issue 5, Pages (November 2016)
Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance  Adam B. Weiner, Ruth Etzioni, Scott E. Eggener 
Volume 56, Issue 2, Pages (August 2009)
Low-risk Prostate Cancer: Identification, Management, and Outcomes
Volume 70, Issue 5, Pages (November 2016)
Volume 69, Issue 6, Pages (June 2016)
Counselling the Prostate Cancer Patient
Prostate Cancer Epidemic in Sight?
The PSA Era is not Over for Prostate Cancer
Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers  Pasquale Rescigno, David Lorente, David Dolling, Roberta Ferraldeschi, Daniel.
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 72, Issue 1, Pages (July 2017)
Volume 66, Issue 2, Pages (August 2014)
Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review  Sven van.
Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia
Volume 74, Issue 2, Pages (August 2018)
Volume 67, Issue 1, Pages (January 2015)
Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.
Volume 50, Issue 5, Pages (November 2006)
CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System
Volume 67, Issue 6, Pages (June 2015)
Volume 66, Issue 5, Pages (November 2014)
Volume 66, Issue 6, Pages (December 2014)
The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.
Volume 70, Issue 6, Pages (December 2016)
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Volume 74, Issue 3, Pages (September 2018)
Volume 70, Issue 1, Pages (July 2016)
Volume 71, Issue 4, Pages (April 2017)
Volume 75, Issue 3, Pages (March 2019)
European Urology is “Your” Journal
Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders
Volume 69, Issue 5, Pages (May 2016)
European Urology Oncology
Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson 
Volume 53, Issue 2, Pages (February 2008)
Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas 
Volume 51, Issue 5, Pages (May 2007)
European Urology Oncology
Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer  Alex P. Hoyle, Adnan Ali, Nicholas D. James, Adrian Cook, Christopher.
Presentation transcript:

Volume 66, Issue 3, Pages 459-465 (September 2014) Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents  Carmel J. Pezaro, Aurelius G. Omlin, Amelia Altavilla, David Lorente, Roberta Ferraldeschi, Diletta Bianchini, David Dearnaley, Christopher Parker, Johann S. de Bono, Gerhardt Attard  European Urology  Volume 66, Issue 3, Pages 459-465 (September 2014) DOI: 10.1016/j.eururo.2013.11.044 Copyright © 2013 European Association of Urology Terms and Conditions

Fig. 1 Waterfall plot showing maximum change (percentage) in prostate-specific antigen (PSA) level from baseline on abiraterone and cabazitaxel treatments. Paired bars represent individual patients. Stars represent patients exposed to enzalutamide prior to cabazitaxel. Increases in PSA level are capped at 50%. European Urology 2014 66, 459-465DOI: (10.1016/j.eururo.2013.11.044) Copyright © 2013 European Association of Urology Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.